Goldman Sachs, Leerink Swann Initiate Coverage of Foundation Medicine | GenomeWeb

NEW YORK (GenomeWeb News) – Coverage of Foundation Medicine was initiated today by Goldman Sachs and Leerink Swann, which gave the cancer genomics analysis firm a Neutral and Outperform rating, respectively.

Goldman Sachs gave the company a six-month share target price of $33, while Leerink Swann gave it a $39 price target. The two investment banks were underwriters in Foundation's initial pubic offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.